Business Context and Reporting Period
Company: InMed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 12, 2025 (Earliest event reported)
Reporting Period: Specific events occurring on June 12 and June 13, 2025.
Key Financial Metrics
This filing is a Current Report on Form 8-K and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses on corporate governance, legal agreements, and shareholder voting outcomes.
Material Changes and Events
- Amendment to Standby Equity Purchase Agreement (SEPA): On June 13, 2025, the Company amended its SEPA with Yorkville. The amendment clarifies "Black Out Period" provisions, allowing the Company to suspend the use of the Registration Statement to delay disclosure of material nonpublic information or to amend the prospectus. During such periods, Yorkville cannot sell shares under the Registration Statement but may do so under exemptions. The Company agreed not to impose Black Out Periods more restrictive than those applied to directors and officers.
- Change in Certifying Accountant: Marcum LLP resigned effective June 12, 2025, following the acquisition of its attest business by CBIZ CPAs P.C. The Audit Committee accepted the resignation and engaged CBIZ as the independent registered public accounting firm for the fiscal year ending June 30, 2025.
- Shareholder Vote Failure: A special meeting held on June 13, 2025, to approve the issuance of up to 20% of outstanding Common Shares under the SEPA failed to achieve a quorum. Consequently, no business was conducted, and the proposal was not voted upon, despite approximately 60% of the votes cast being in favor.
Guidance, Outlook, and Risks
- Future Actions: The Board is assessing whether to hold a subsequent special meeting or include the Share Issuance Proposal in the proxy statement for the 2025 annual general meeting.
- Going Concern: The filing notes that Marcum's report for the fiscal year ended June 30, 2024, included an explanatory paragraph regarding substantial doubt about the Company's ability to continue as a going concern.
- Internal Controls: A previously disclosed material weakness regarding the adequacy of resources for financial reporting (related to pre-funded warrants and acquisition accounting) was determined to be remediated as of June 30, 2024. No disagreements or reportable events occurred between the Company and Marcum during the relevant periods.
- Forward-Looking Statements: The filing contains forward-looking statements regarding business strategy and future plans, which are subject to risks and uncertainties.
Investor Verification Checklist
- Verify the status of the SEPA Share Issuance Proposal and the timeline for the next shareholder vote.
- Review the full text of the Amendment to the SEPA (Exhibit 10.1) to understand specific restrictions on share sales during Black Out Periods.
- Confirm the transition of audit responsibilities from Marcum LLP to CBIZ CPAs P.C. and review the new auditor's engagement terms.
- Assess the Company's liquidity position given the historical "going concern" qualification noted in the prior fiscal year's audit report.
- Monitor upcoming filings for the definitive proxy statement regarding the 2025 annual general meeting.